Angus George DALGLEISH et al. HUMAN PROSTATE CELL LINES IN CANCER TREATMENT 37945-0054



Figure 1

Patient 406






Figure 2



1= Molecular weight markers, 2= PNT2 lysate, 3= 1542 lysate, 4=DU145 lysate, 5=LnCap lysate


Angus George DALGLEISH et al. HUMAN PROSTATE CELL LINES IN CANCER TREATMENT 37945-0054


Figure 2 (continued)




1= Molecular weight markers, 2= PNT2 lysate, 3= 1542 lysate, 4=DU145 lysate, 5=LnCap lysate

Figur 3










Figure 3 (continued)





Figure 4

Patient 110








Figure 4 (continued)










Figure 5









Patient	Slope Pre treatment	Slope Post treatment	Doubling time (days) Pre- treatment	Doubling time (days) Post treatment	
1	0.0038	0.0014	182	495	p = 0.04
2	0.0065	0.0068	106	102	
3	0.0046	0.0033	152	213	
4	0.0041	0.0032	169	217	
2	0.0043	0.0018	161	377	p = 0.08
9	0.0021	0.0235	324	29	
7	0.0038	0.0015	184	475	p = 0.1
8	0.0046	0.0053	150	130	
6	600'0	0.0041	22	168	p = 0.005
10	0.0113	0.0064	61	109	p = 0.009
11	0.003	0.0027	234	261	
12	0.0072	0.0028	96	248	p = 0.001
13	0.0075	0.0123	6	26	
14	0.0157	0.0024	44	294	p = 0.004
15	0.0002	0.0033	2999	213	

Angus George DALGLEISH et al. HUMAN PROSTATE CELL LINES IN CANCER TREATMENT 37945-0054

Figure 10

Ratio of PSA Doubling Times, Post:Pre

3.5

2.5

1.5

0.5

7